About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Abbotts New Drug-coated Stent Promising

by Medindia Content Team on November 29, 2007 at 11:41 AM
Font : A-A+

Abbotts New Drug-coated Stent Promising

Abbott Laboratories new drug-coated heart stent, Xience V, seems to outperform market leader Taxus 2 and so could win federal approval in US.

There was no difference between Xience and Taxus in terms of deaths or heart attack rates. But the newer stent's advantage over Taxus in protecting against new clogging led to fewer repeat procedures to keep patients' arteries open. The studies were conducted over two years.

Advertisement

Analysts predict that if the F.D.A. allows it on the market, Xience will quickly become a best seller.

The analysts estimate that Xience could gain as much as 45 percent of a $1.8 billion American annual market for drug-coated stents over the next few years. That would include Xience sales under a different name, the Promus stent, which would be marketed in an arrangement with Boston Scientific.
Advertisement

Stents are small metal-mesh cylinders inserted into coronary arteries after blockages have been cleared to keep them propped open. Since 2003, the market has been dominated by drug-coated devices because they do a better job of preventing new clogging than the bare-metal stents that preceded them.

But sales and use have fallen in the last 18 months on safety concerns and a belief among some cardiologists that many patients getting stents to relieve chest pain can fare just as well by relying on drugs and lifestyle changes like quitting smoking.

Based in part on experience in Europe, where all four stents and several others are on the market and prices have fallen below $1,000 for drug-coated devices, some health care providers hope that the new devices will lead both to improved outcomes for patients and a price war. The average price for the devices in the United States now is more than $2,000.

An F.D.A. staff review of the data noted that there was too little long-term evidence to reach any conclusions about the chances that clots could form in Xience stents long after they were implanted. Such clotting, a rare but potentially fatal problem, has been linked to drug-coated stents now on the market.

Source: Medindia
GPL/P
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Heart Attack - Treatment
The treatment of heart attack is aimed at restoring the blood flow and should be started soon after ...
Drug-eluting Stents Vs Bare-metal Ones
Latest findings published in the November 20th issue of the Journal of the American College of ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use